|Articles|June 1, 2008

Pharmaceutical Executive

  • Pharmaceutical Executive-06-01-2008
  • Volume 0
  • Issue 0

Keeshia Muhammad, Teva Specialty Pharmaceuticals

Keeshia Muhammad

Keeshia Muhammad

Executive Director, Marketing, Teva Specialty Pharmaceuticals

MAKES PHARMA A BETTER PLACE: The Healthcare Businesswomen's Association

REWARD: Standing ovations for marketing teams from the sales force

Keeshia Muhammad says much of what you need to know about co-promotion you learned in kindergarten. "It's about collaborating with people, with the foundation of integrity, trust, and respect. Hidden agendas ultimately tarnish relationships as you start to build a team."

Keeshia Muhammad

And she should know. Muhammad worked on the Merck/Schering-Plough joint venture for Zetia and Vytorin, maintained Altana's voice in its COPD hopeful PDE-4 inhibitor partnership with Pfizer, and managed Altana's co-promotion of Alvesco with Sanofi-Aventis. While she may have played nice in the past, Muhammad is showing an edge in her new role. Under her leadership, Teva's flagship asthma brand ProAir HFA has nearly doubled its market share to 60 percent. So how does she do it? "I bring passion and energy to the table," she says. "I always have people asking me, 'Can I have a dose of that?'"

Articles in this issue

over 18 years ago

Mary Szela, Abbott

over 18 years ago

Mightier Than the Sword

over 18 years ago

Eric Floyd, Cephalon

over 18 years ago

Nancy Phelan, Wyeth

over 18 years ago

Tightening the Chain

over 18 years ago

Kurt Graves, Vertex

over 18 years ago

Wendy Niebler, Shire

over 18 years ago

Perfectly Imperfect

over 18 years ago

Relaunching Reform

Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.